Are T2WI PI-RADS sub-scores of transition zone prostate lesions biased by DWI information? A multi-reader, single-center study.

According to PI-RADS v2.1, T2-weighted imaging (T2WI) is the dominant sequence for transition zone (TZ) lesions. This study aimed to assess, whether diffusion-weighted imaging (DWI) information influences the assignment of T2WI scores. Out of 283 prostate MRI examinations with correlated biopsy results, fourty-four patients were selected retrospectively: first, 22 patients with a TZ lesion with T2WI and DWI scores ≥ 4, to represent lesions with unequivocal suspicion on T2WI and DWI. Second, 22 additional patients with TZ lesions of similar T2WI appearance but with corresponding DWI score ≤ 3 were added as control. Four residents and one board-certified radiologist each performed two assessments of the included patients: First, only T2WI was available (T2-only read); second, both T2WI and DWI sequences were available (biparametric read). Lesion scores were assessed using Wilcoxon signed-rank test, inter-reader agreement using weighted kappa and Kendall's W statistics, and sensitivity/specificity using McNemar test. The T2WI scores were significantly different between the T2-only and biparametric read for 3 out of 4 residents (p ≤ 0.049) but not for the radiologist. The overall PI-RADS scores derived from the two reading sessions differed considerably for 35/220 cases (all readers pooled). Inter-reader agreement was fair for the T2WI and overall PI-RADS scores (mean kappa 0.27-0.30) and moderate for the DWI scores (mean kappa 0.43). For inexperienced readers, assessment of T2WI is variable and potentially biased by availability of DWI information, which can lead to changes of overall PI-RADS score and consequently clinical management. Assessment of T2WI should be performed before reviewing DWI to ensure non-biased interpretation of TZ lesions in the dominant sequence.

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: KS Zhang, P. Mayer, PA Glemser, AA Tavakoli, M. Keymling, LT Rotkopf, M. Görtz, T. Hielscher and M. Hohenfellner have nothing to declare. C. Meinzer declares: Research funding: Bundesministerium für Wirtschaft und Klimaschutz (BMWK): 01MT21004B. HU Kauczor declares: Consulting fee or honoraria (speakers bureau): Siemens, Philips, Sanofi, Median; grants/research support: Siemens, Philips, Boehringer Ingelheim. A. Stenzinger declares: Research funding: Bayer, Bristol-Myers Squibb, Chugai, and Incyte; speaker’s honoraria: Aignostics, Amgen, Astra Zeneca, AGCT, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seagen, Seattle Genetics, Takeda, and Thermo Fisher. D. Bonekamp declares: Payment for lectures: Bayer Vital. HP Schlemmer declares: Consulting fee or honorarium: Siemens, Curagita, Profound, Bayer; travel support: Siemens, Curagita, Profound, Bayer; board member: Curagita; consultancy: Curagita, Bayer; grants/grants pending: BMBF, Deutsche Krebshilfe, Dietmar-Hopp-Stiftung, Roland-Ernst-Stiftung; payment for lectures: Siemens, Curagita, Profound, Bayer.